Always aiming at high quality services coupled to true customer focus, Biomedcode has built its reputation steadily over the years gaining the trust and respect of its clients. Since its establishment, Biomedcode has attracted clients from Europe, the United States, Asia and Australia some of them ranked among the top 5 pharmaceutical companies worldwide. Preclinical data generated following our successful collaboration with our clients, have been incorporated in IND applications for FDA, SFDA & EMEA approval.
UCB Celltech & Biomedcode co-author a paper demonstrating that CAIA in the human TNF transgenic (Tg1278TNFko) mice is a well-suited animal model for testing the next generation of therapeutics targeting human TNFα in rheumatoid arthritis.
Biomedcode’s Tg197 transgenic model of rheumatoid arthritis was used to test the efficacy of various anti-TNF antibodies.
A publication on a novel antibody characterization where the experiments were performed using Tg197 transgenic mouse model by Biomedcode.